Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel Free AARD Stock Alerts

Aardvark Therapeutics (AARD) Competitors

Aardvark Therapeutics logo
$5.47 +0.20 (+3.80%)
Closing price 04:00 PM Eastern
Extended Trading
$5.38 -0.09 (-1.57%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AARD vs. LRMR, AURA, RGNX, CTNM, and VALN

Should you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Larimar Therapeutics (LRMR), Aura Biosciences (AURA), REGENXBIO (RGNX), Contineum Therapeutics (CTNM), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry.

How does Aardvark Therapeutics compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

91.9% of Larimar Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Larimar Therapeutics had 3 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 4 mentions for Larimar Therapeutics and 1 mentions for Aardvark Therapeutics. Larimar Therapeutics' average media sentiment score of 0.66 beat Aardvark Therapeutics' score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Larimar Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aardvark Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Larimar Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 311.47%. Aardvark Therapeutics has a consensus price target of $22.60, suggesting a potential upside of 313.16%. Given Aardvark Therapeutics' higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Larimar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Larimar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10
Aardvark Therapeutics
1 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.62

Larimar Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Aardvark Therapeutics has a beta of 5.11, suggesting that its stock price is 411% more volatile than the S&P 500.

Aardvark Therapeutics' return on equity of -44.59% beat Larimar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Larimar TherapeuticsN/A -137.70% -101.43%
Aardvark Therapeutics N/A -44.59%-41.51%

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Larimar TherapeuticsN/AN/A-$165.67M-$2.21N/A
Aardvark TherapeuticsN/AN/A-$57.59M-$2.93N/A

Summary

Larimar Therapeutics beats Aardvark Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Aura Biosciences is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aura BiosciencesN/AN/A-$106.19M-$1.79N/A
Aardvark TherapeuticsN/AN/A-$57.59M-$2.93N/A

Aura Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Aardvark Therapeutics has a beta of 5.11, suggesting that its stock price is 411% more volatile than the S&P 500.

In the previous week, Aura Biosciences had 19 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 20 mentions for Aura Biosciences and 1 mentions for Aardvark Therapeutics. Aura Biosciences' average media sentiment score of 0.32 beat Aardvark Therapeutics' score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aura Biosciences
4 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aardvark Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aura Biosciences currently has a consensus price target of $21.50, suggesting a potential upside of 141.57%. Aardvark Therapeutics has a consensus price target of $22.60, suggesting a potential upside of 313.16%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Aura Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aura Biosciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Aardvark Therapeutics
1 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.62

96.8% of Aura Biosciences shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aardvark Therapeutics' return on equity of -44.59% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aura BiosciencesN/A -71.25% -59.06%
Aardvark Therapeutics N/A -44.59%-41.51%

Summary

Aardvark Therapeutics beats Aura Biosciences on 8 of the 13 factors compared between the two stocks.

How does Aardvark Therapeutics compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Aardvark Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$170.44M2.79-$193.88M-$3.76N/A
Aardvark TherapeuticsN/AN/A-$57.59M-$2.93N/A

REGENXBIO has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Aardvark Therapeutics has a beta of 5.11, suggesting that its share price is 411% more volatile than the S&P 500.

In the previous week, REGENXBIO and REGENXBIO both had 1 articles in the media. REGENXBIO's average media sentiment score of 0.30 beat Aardvark Therapeutics' score of 0.00 indicating that REGENXBIO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
REGENXBIO
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aardvark Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

REGENXBIO currently has a consensus price target of $27.50, suggesting a potential upside of 198.26%. Aardvark Therapeutics has a consensus price target of $22.60, suggesting a potential upside of 313.16%. Given Aardvark Therapeutics' higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than REGENXBIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
Aardvark Therapeutics
1 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.62

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aardvark Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -113.75%. Aardvark Therapeutics' return on equity of -44.59% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-113.75% -103.12% -37.83%
Aardvark Therapeutics N/A -44.59%-41.51%

Summary

REGENXBIO and Aardvark Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Aardvark Therapeutics has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum Therapeutics$50M10.75-$59.98M-$2.18N/A
Aardvark TherapeuticsN/AN/A-$57.59M-$2.93N/A

Contineum Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Aardvark Therapeutics has a beta of 5.11, suggesting that its share price is 411% more volatile than the S&P 500.

In the previous week, Contineum Therapeutics had 5 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Aardvark Therapeutics. Contineum Therapeutics' average media sentiment score of 0.38 beat Aardvark Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aardvark Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Contineum Therapeutics currently has a consensus price target of $19.50, suggesting a potential upside of 35.51%. Aardvark Therapeutics has a consensus price target of $22.60, suggesting a potential upside of 313.16%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Contineum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aardvark Therapeutics
1 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.62

Contineum Therapeutics' return on equity of -30.08% beat Aardvark Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -30.08% -28.27%
Aardvark Therapeutics N/A -44.59%-41.51%

Summary

Contineum Therapeutics and Aardvark Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Valneva?

Aardvark Therapeutics (NASDAQ:AARD) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

11.4% of Valneva shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Valneva had 4 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 5 mentions for Valneva and 1 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.00 equaled Valneva'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aardvark Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Valneva
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aardvark Therapeutics has a beta of 5.11, suggesting that its share price is 411% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.

Aardvark Therapeutics has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aardvark TherapeuticsN/AN/A-$57.59M-$2.93N/A
Valneva$197.56M2.31-$130.33M-$1.58N/A

Aardvark Therapeutics presently has a consensus price target of $22.60, indicating a potential upside of 313.16%. Valneva has a consensus price target of $11.98, indicating a potential upside of 126.37%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aardvark Therapeutics is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aardvark Therapeutics
1 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.62
Valneva
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

Aardvark Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -67.64%. Aardvark Therapeutics' return on equity of -44.59% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Aardvark TherapeuticsN/A -44.59% -41.51%
Valneva -67.64%-76.81%-26.33%

Summary

Aardvark Therapeutics beats Valneva on 8 of the 14 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AARD vs. The Competition

Export
MetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$114.97M$3.39B$6.24B$11.86B
Dividend YieldN/A2.20%2.73%5.21%
P/E RatioN/A38.8529.0428.48
Price / SalesN/A157.28477.1060.43
Price / CashN/A57.8827.6236.52
Price / Book1.127.039.676.67
Net Income-$57.59M$23.62M$3.55B$332.64M
7 Day Performance-2.15%3.67%1.70%2.01%
1 Month Performance27.21%7.17%5.62%9.19%
1 Year Performance-48.10%67.04%34.42%39.59%

Aardvark Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AARD
Aardvark Therapeutics
1.937 of 5 stars		$5.47
+3.8%		$22.60
+313.2%		N/A$114.97MN/AN/A18
LRMR
Larimar Therapeutics
4.065 of 5 stars		$4.54
+0.9%		$16.50
+263.4%		N/A$467.47MN/AN/A30
AURA
Aura Biosciences
2.8697 of 5 stars		$7.27
+0.1%		$20.50
+182.0%		N/A$466.09MN/AN/A50
RGNX
REGENXBIO
2.3665 of 5 stars		$8.76
-2.6%		$27.50
+213.9%		N/A$464.04M$170.44MN/A370
CTNM
Contineum Therapeutics
1.9846 of 5 stars		$12.41
-0.1%		$19.50
+57.1%		N/A$463.71M$50MN/A31

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel